Efficacy of treatments for depression in children and adolescents
- Carr, Victoria, Boyd, Candice
- Authors: Carr, Victoria , Boyd, Candice
- Date: 2003
- Type: Text , Journal article
- Relation: Behaviour Change Vol. 20, no. 2 (2003), p. 103-108
- Full Text:
- Reviewed:
- Description: Depression is a highly complex mental disorder that for many years was believed to be absent in children and adolescents. It is now accepted that depression not only exists in this age group, but also is a major mental health problem (Weller & Weller, 2000a). Research suggests that the prevalence of depression in Australian children and adolescents is around 14% (Boyd, Kostanski, Gullone, Ollendick, & Shek, 2000). As depression appears to be highly prevalent, it is essential that efficacious treatments are identified, and that effective treatment strategies are established that best alleviate depressive symptoms in children and adolescents. In light of this need, this article details the criteria used to identify depression in children and adolescents, and examines the available evidence for the use of pharmacological and psychotherapeutic approaches in the treatment of depression in children and adolescents.
- Description: C1
- Description: 2003000489
- Authors: Carr, Victoria , Boyd, Candice
- Date: 2003
- Type: Text , Journal article
- Relation: Behaviour Change Vol. 20, no. 2 (2003), p. 103-108
- Full Text:
- Reviewed:
- Description: Depression is a highly complex mental disorder that for many years was believed to be absent in children and adolescents. It is now accepted that depression not only exists in this age group, but also is a major mental health problem (Weller & Weller, 2000a). Research suggests that the prevalence of depression in Australian children and adolescents is around 14% (Boyd, Kostanski, Gullone, Ollendick, & Shek, 2000). As depression appears to be highly prevalent, it is essential that efficacious treatments are identified, and that effective treatment strategies are established that best alleviate depressive symptoms in children and adolescents. In light of this need, this article details the criteria used to identify depression in children and adolescents, and examines the available evidence for the use of pharmacological and psychotherapeutic approaches in the treatment of depression in children and adolescents.
- Description: C1
- Description: 2003000489
My Road Ahead study protocol: A randomised controlled trial of an online psychological intervention for men following treatment for localised prostate cancer
- Wootten, Addie, Abbott, Jo-Anne, Chisholm, Katherine, Austin, David, Klein, Britt, McCabe, Marita, Meyer, Denny, Costello, Anthony, Murphy, Declan
- Authors: Wootten, Addie , Abbott, Jo-Anne , Chisholm, Katherine , Austin, David , Klein, Britt , McCabe, Marita , Meyer, Denny , Costello, Anthony , Murphy, Declan
- Date: 2014
- Type: Text , Journal article
- Relation: BMC Cancer Vol. 14, no. 1 (2014), p.83
- Full Text:
- Reviewed:
- Description: Background: There is a need for psychosocial interventions for men with prostate cancer to promote adaptive coping with the challenges and distress associated with diagnosis, treatment and recovery. In addition, interventions are needed that help to overcome barriers to psychosocial treatment such as limited face-to-face psychosocial support services, a shortage of adequately trained professionals, geographical distance, perceived and personal stigma and a preference for consumer-centric and self-directed learning. My Road Ahead is an online cognitive behaviour therapy (CBT) intervention for prostate cancer. This protocol describes a randomised controlled trial (RCT) that will evaluate the efficacy of this online intervention alone, the intervention in combination with a moderated online forum, and the moderated online forum alone. Methods/design: This study utilises a RCT design with three groups receiving: 1) the 6-module My Road Ahead intervention alone; 2) the My Road Ahead intervention plus a moderated online forum; and 3) the moderated online forum alone. It is expected that 150 men with localised prostate cancer will be recruited into the RCT. Online measures will assess men's psychological distress as well as sexual and relationship adjustment at baseline, post-intervention, 3 month follow-up and 6 month follow-up. The study is being conducted in Australia and participants will be recruited from April 2012 to Feb 2014. The primary aim of this study is to evaluate the efficacy of My Road Ahead in reducing psychological distress. Discussion: To our knowledge, My Road Ahead is the first self-directed online psychological intervention developed for men who have been treated for localised prostate cancer. The RCT will assess the efficacy of this intervention in improving psychological well-being, sexual satisfaction, relationship satisfaction and overall quality of life. If successful, this intervention could provide much needed support to men receiving treatment for localised prostate cancer in a highly accessible manner. Trial registration: Australian New Zealand Clinical Trials Registry Identifier: ACTRN12611000278932. © 2014 Wootten et al.; licensee BioMed Central Ltd.
- Authors: Wootten, Addie , Abbott, Jo-Anne , Chisholm, Katherine , Austin, David , Klein, Britt , McCabe, Marita , Meyer, Denny , Costello, Anthony , Murphy, Declan
- Date: 2014
- Type: Text , Journal article
- Relation: BMC Cancer Vol. 14, no. 1 (2014), p.83
- Full Text:
- Reviewed:
- Description: Background: There is a need for psychosocial interventions for men with prostate cancer to promote adaptive coping with the challenges and distress associated with diagnosis, treatment and recovery. In addition, interventions are needed that help to overcome barriers to psychosocial treatment such as limited face-to-face psychosocial support services, a shortage of adequately trained professionals, geographical distance, perceived and personal stigma and a preference for consumer-centric and self-directed learning. My Road Ahead is an online cognitive behaviour therapy (CBT) intervention for prostate cancer. This protocol describes a randomised controlled trial (RCT) that will evaluate the efficacy of this online intervention alone, the intervention in combination with a moderated online forum, and the moderated online forum alone. Methods/design: This study utilises a RCT design with three groups receiving: 1) the 6-module My Road Ahead intervention alone; 2) the My Road Ahead intervention plus a moderated online forum; and 3) the moderated online forum alone. It is expected that 150 men with localised prostate cancer will be recruited into the RCT. Online measures will assess men's psychological distress as well as sexual and relationship adjustment at baseline, post-intervention, 3 month follow-up and 6 month follow-up. The study is being conducted in Australia and participants will be recruited from April 2012 to Feb 2014. The primary aim of this study is to evaluate the efficacy of My Road Ahead in reducing psychological distress. Discussion: To our knowledge, My Road Ahead is the first self-directed online psychological intervention developed for men who have been treated for localised prostate cancer. The RCT will assess the efficacy of this intervention in improving psychological well-being, sexual satisfaction, relationship satisfaction and overall quality of life. If successful, this intervention could provide much needed support to men receiving treatment for localised prostate cancer in a highly accessible manner. Trial registration: Australian New Zealand Clinical Trials Registry Identifier: ACTRN12611000278932. © 2014 Wootten et al.; licensee BioMed Central Ltd.
Investing in big ideas: utilisation and cost of Medicare Allied Health services in Australia under the Chronic Disease Management initiative in primary care
- Cant, Robyn, Foster, Michele
- Authors: Cant, Robyn , Foster, Michele
- Date: 2011
- Type: Text , Journal article
- Relation: Australian health review : a publication of the Australian Hospital Association Vol. 35, no. 4 (2011), p. 468-474
- Full Text:
- Reviewed:
- Description: To critically examine utilisation of the 13 allied health services provided through Medicare Chronic Disease Management program and related general practitioner (GP) care planning initiatives.
- Authors: Cant, Robyn , Foster, Michele
- Date: 2011
- Type: Text , Journal article
- Relation: Australian health review : a publication of the Australian Hospital Association Vol. 35, no. 4 (2011), p. 468-474
- Full Text:
- Reviewed:
- Description: To critically examine utilisation of the 13 allied health services provided through Medicare Chronic Disease Management program and related general practitioner (GP) care planning initiatives.
Bronchial thermoplasty versus mepolizumab : comparison of outcomes in a severe asthma clinic
- Langton, David, Sha, Joy, Guo, Suzy, Sharp, Julie, Plummer, Virginia
- Authors: Langton, David , Sha, Joy , Guo, Suzy , Sharp, Julie , Plummer, Virginia
- Date: 2020
- Type: Text , Journal article
- Relation: Respirology Vol. 25, no. 12 (2020), p. 1243-1249
- Full Text:
- Reviewed:
- Description: Background and objective: BT and interleukin-blocking monoclonal antibodies are both effective therapies for severe asthma, but there have been no direct comparisons between the two treatments. The aim of this study was to compare the efficacy and safety of BT and mepolizumab, in a real-world setting. Methods: Patients with severe asthma despite optimized inhaler therapy were drawn from a severe asthma clinic in a tertiary hospital. Every patient commencing therapy with BT or mepolizumab was prospectively included in a national registry. At predetermined assessment points over a 12-month period, assessments were made of ACQ, spirometry, oral corticosteroid requiring exacerbations, reliever medication and maintenance oral corticosteroid use. Results: A total of 91 patients with severe asthma participated: mean ACQ score 3.5 ± 1.0, FEV1 51.4 ± 17.7%, maintenance oral steroids 48.3% and 11.5 ± 10.0 inhalations/day reliever therapy. Forty-seven patients received mepolizumab and 44 received BT. Baseline characteristics were similar except significantly higher blood eosinophil count in the mepolizumab group. At 12 months, there were no differences between treatment outcomes for ACQ (1.9 ± 1.3 mepolizumab vs 1.7 ± 1.3 BT), exacerbation rate (0.9 ± 1.1 vs 0.9 ± 1.5), reduction in reliever use (−6.3 ± 10.5 vs −5.0 ± 8.8 puffs/day) or reduction in oral corticosteroids (−3.3 ± 7.5 vs − 5.8 ± 6.7 mg/day). The FEV1 improved equally (160 ± 290 vs 150 ± 460 mL). Readmission or prolonged admission was observed in 18.2% of BT patients, whilst 25.5% of mepolizumab patients had discontinued treatment at 12 months, 14.9% due to an adverse event or non-compliance. Conclusion: The results suggest that BT is as efficacious as mepolizumab for the treatment of severe asthma. © 2020 Asian Pacific Society of Respirology. *Please note that there are multiple authors for this article therefore only the name of the first 5 including Federation University Australia affiliate “Virginia Plummer” is provided in this record**
- Authors: Langton, David , Sha, Joy , Guo, Suzy , Sharp, Julie , Plummer, Virginia
- Date: 2020
- Type: Text , Journal article
- Relation: Respirology Vol. 25, no. 12 (2020), p. 1243-1249
- Full Text:
- Reviewed:
- Description: Background and objective: BT and interleukin-blocking monoclonal antibodies are both effective therapies for severe asthma, but there have been no direct comparisons between the two treatments. The aim of this study was to compare the efficacy and safety of BT and mepolizumab, in a real-world setting. Methods: Patients with severe asthma despite optimized inhaler therapy were drawn from a severe asthma clinic in a tertiary hospital. Every patient commencing therapy with BT or mepolizumab was prospectively included in a national registry. At predetermined assessment points over a 12-month period, assessments were made of ACQ, spirometry, oral corticosteroid requiring exacerbations, reliever medication and maintenance oral corticosteroid use. Results: A total of 91 patients with severe asthma participated: mean ACQ score 3.5 ± 1.0, FEV1 51.4 ± 17.7%, maintenance oral steroids 48.3% and 11.5 ± 10.0 inhalations/day reliever therapy. Forty-seven patients received mepolizumab and 44 received BT. Baseline characteristics were similar except significantly higher blood eosinophil count in the mepolizumab group. At 12 months, there were no differences between treatment outcomes for ACQ (1.9 ± 1.3 mepolizumab vs 1.7 ± 1.3 BT), exacerbation rate (0.9 ± 1.1 vs 0.9 ± 1.5), reduction in reliever use (−6.3 ± 10.5 vs −5.0 ± 8.8 puffs/day) or reduction in oral corticosteroids (−3.3 ± 7.5 vs − 5.8 ± 6.7 mg/day). The FEV1 improved equally (160 ± 290 vs 150 ± 460 mL). Readmission or prolonged admission was observed in 18.2% of BT patients, whilst 25.5% of mepolizumab patients had discontinued treatment at 12 months, 14.9% due to an adverse event or non-compliance. Conclusion: The results suggest that BT is as efficacious as mepolizumab for the treatment of severe asthma. © 2020 Asian Pacific Society of Respirology. *Please note that there are multiple authors for this article therefore only the name of the first 5 including Federation University Australia affiliate “Virginia Plummer” is provided in this record**
The impact of a novel mimicry task for increasing emotion recognition in adults with autism spectrum disorder and alexithymia : protocol for a randomized controlled trial
- Caine, Joshua, Klein, Britt, Edwards, Stephen
- Authors: Caine, Joshua , Klein, Britt , Edwards, Stephen
- Date: 2021
- Type: Text , Journal article
- Relation: JMIR Research Protocols Vol. 10, no. 6 (2021), p.
- Full Text:
- Reviewed:
- Description: Background: Impaired facial emotion expression recognition (FEER) has typically been considered a correlate of autism spectrum disorder (ASD). Now, the alexithymia hypothesis is suggesting that this emotion processing problem is instead related to alexithymia, which frequently co-occurs with ASD. By combining predictive coding theories of ASD and simulation theories of emotion recognition, it is suggested that facial mimicry may improve the training of FEER in ASD and alexithymia. Objective: This study aims to evaluate a novel mimicry task to improve FEER in adults with and without ASD and alexithymia. Additionally, this study will aim to determine the contributions of alexithymia and ASD to FEER ability and assess which of these 2 populations benefit from this training task. Methods: Recruitment will primarily take place through an ASD community group with emphasis put on snowball recruiting. Included will be 64 consenting adults equally divided between participants without an ASD and participants with an ASD. Participants will be screened online using the Kessler Psychological Distress Scale (K-10; cut-off score of 22), Autism Spectrum Quotient (AQ-10), and Toronto Alexithymia Scale (TAS-20) followed by a clinical interview with a provisional psychologist at the Federation University psychology clinic. The clinical interview will include assessment of ability, anxiety, and depression as well as discussion of past ASD diagnosis and confirmatory administration of the Autism Mental Status Exam (AMSE). Following the clinical interview, the participant will complete the Bermond-Vorst Alexithymia Questionnaire (BVAQ) and then undertake a baseline assessment of FEER. Consenting participants will then be assigned using a permuted blocked randomization method into either the control task condition or the mimicry task condition. A brief measure of satisfaction of the task and a debriefing session will conclude the study. Results: The study has Federation University Human Research Ethics Committee approval and is registered with the Australian New Zealand Clinical Trials. Participant recruitment is predicted to begin in the third quarter of 2021. Conclusions: This study will be the first to evaluate the use of a novel facial mimicry task condition to increase FEER in adults with ASD and alexithymia. If efficacious, this task could prove useful as a cost-effective adjunct intervention that could be used at home and thus remove barriers to entry. This study will also explore the unique effectiveness of this task in people without an ASD, with an ASD, and with alexithymia. © 2021 JMIR Research Protocols.
- Authors: Caine, Joshua , Klein, Britt , Edwards, Stephen
- Date: 2021
- Type: Text , Journal article
- Relation: JMIR Research Protocols Vol. 10, no. 6 (2021), p.
- Full Text:
- Reviewed:
- Description: Background: Impaired facial emotion expression recognition (FEER) has typically been considered a correlate of autism spectrum disorder (ASD). Now, the alexithymia hypothesis is suggesting that this emotion processing problem is instead related to alexithymia, which frequently co-occurs with ASD. By combining predictive coding theories of ASD and simulation theories of emotion recognition, it is suggested that facial mimicry may improve the training of FEER in ASD and alexithymia. Objective: This study aims to evaluate a novel mimicry task to improve FEER in adults with and without ASD and alexithymia. Additionally, this study will aim to determine the contributions of alexithymia and ASD to FEER ability and assess which of these 2 populations benefit from this training task. Methods: Recruitment will primarily take place through an ASD community group with emphasis put on snowball recruiting. Included will be 64 consenting adults equally divided between participants without an ASD and participants with an ASD. Participants will be screened online using the Kessler Psychological Distress Scale (K-10; cut-off score of 22), Autism Spectrum Quotient (AQ-10), and Toronto Alexithymia Scale (TAS-20) followed by a clinical interview with a provisional psychologist at the Federation University psychology clinic. The clinical interview will include assessment of ability, anxiety, and depression as well as discussion of past ASD diagnosis and confirmatory administration of the Autism Mental Status Exam (AMSE). Following the clinical interview, the participant will complete the Bermond-Vorst Alexithymia Questionnaire (BVAQ) and then undertake a baseline assessment of FEER. Consenting participants will then be assigned using a permuted blocked randomization method into either the control task condition or the mimicry task condition. A brief measure of satisfaction of the task and a debriefing session will conclude the study. Results: The study has Federation University Human Research Ethics Committee approval and is registered with the Australian New Zealand Clinical Trials. Participant recruitment is predicted to begin in the third quarter of 2021. Conclusions: This study will be the first to evaluate the use of a novel facial mimicry task condition to increase FEER in adults with ASD and alexithymia. If efficacious, this task could prove useful as a cost-effective adjunct intervention that could be used at home and thus remove barriers to entry. This study will also explore the unique effectiveness of this task in people without an ASD, with an ASD, and with alexithymia. © 2021 JMIR Research Protocols.
Physiotherapy for freezing of gait in Parkinson's disease: a systematic review and meta-analysis
- Miller, Kyle, Suarez-Iglesias, David, Seijo-Martinez, Manuel, Ayan, Carlos
- Authors: Miller, Kyle , Suarez-Iglesias, David , Seijo-Martinez, Manuel , Ayan, Carlos
- Date: 2020
- Type: Text , Journal article
- Relation: Revista De Neurologia Vol. 70, no. 5 (Mar 2020), p. 161-170
- Full Text:
- Reviewed:
- Description: Introduction. Freezing of gait (FOG) is one of the most severe symptoms associated with Parkinson's disease (PD). Physiotherapy treatment could be an effective strategy for treating FOG, but no systematic review has been carried out in this regard. Aim. To identify the characteristics, methodological quality, and main outcomes of the studies that have analyzed the effects of physiotherapy interventions in FOG up to date, by performing a systematic review and a meta-analysis. Patients and methods. Four electronic databases were searched in order to find randomized controlled trials that provided information regarding the effects of any kind of physiotherapy treatment on FOG. The methodological quality of the included investigations was assessed by means of the PEDro scale. Results. Twelve studies were identified for inclusion into the qualitative analysis, with four randomized controlled trials included in the final meta-analysis. The quality of the trials was generally good. Those physiotherapy modalities including cues were more effective for treating FOG than traditional physiotherapy approaches. The meta-analysis indicated that physiotherapy interventions had a significantly greater impact on FOG than control comparisons. Conclusions. Physiotherapy treatment, especially those modalities including visual and auditory cueing, should be prescribed to PD patients with FOG. Future studies including PD patients with cognitive impairment and FOG objective measurement tools are need to complete the existing scientific evidence.
- Authors: Miller, Kyle , Suarez-Iglesias, David , Seijo-Martinez, Manuel , Ayan, Carlos
- Date: 2020
- Type: Text , Journal article
- Relation: Revista De Neurologia Vol. 70, no. 5 (Mar 2020), p. 161-170
- Full Text:
- Reviewed:
- Description: Introduction. Freezing of gait (FOG) is one of the most severe symptoms associated with Parkinson's disease (PD). Physiotherapy treatment could be an effective strategy for treating FOG, but no systematic review has been carried out in this regard. Aim. To identify the characteristics, methodological quality, and main outcomes of the studies that have analyzed the effects of physiotherapy interventions in FOG up to date, by performing a systematic review and a meta-analysis. Patients and methods. Four electronic databases were searched in order to find randomized controlled trials that provided information regarding the effects of any kind of physiotherapy treatment on FOG. The methodological quality of the included investigations was assessed by means of the PEDro scale. Results. Twelve studies were identified for inclusion into the qualitative analysis, with four randomized controlled trials included in the final meta-analysis. The quality of the trials was generally good. Those physiotherapy modalities including cues were more effective for treating FOG than traditional physiotherapy approaches. The meta-analysis indicated that physiotherapy interventions had a significantly greater impact on FOG than control comparisons. Conclusions. Physiotherapy treatment, especially those modalities including visual and auditory cueing, should be prescribed to PD patients with FOG. Future studies including PD patients with cognitive impairment and FOG objective measurement tools are need to complete the existing scientific evidence.
- «
- ‹
- 1
- ›
- »